Apart from IPF, extensive research has shown that blocking the ATX-LPA-LPAR axis can have promising therapeutic benefits on a variety of illnesses, including cancers of the breast, ovary, pancreas and liver, cardiovascular diseases, pregnancy induced hypertension (preeclamsia), inflammation induced systemic bone loss, rheumatoid arthritis, and suppression of antitumor immunity [1,2,3,4,5,16,17,21,22,23,24,25,26]. The gene discussed is ENPP2; the disease is rheumatoid arthritis.